In a significant leap for cancer treatment in the region, UC San Diego Health has announced the availability of groundbreaking immunotherapy for patients battling metastatic melanoma. The hospital is the first in the region to provide a personalized cellular therapy approved by the FDA, known as tumor-infiltrating lymphocytes (TIL). Patients with advanced melanoma, particularly those for whom other treatments have failed, now have a new option that specifically leverages their immune system to fight the disease.
According to a statement by Gregory Daniels, MD, PhD, at UC San Diego Health, this single-dose immunotherapy utilizes a patient’s T-cells and turns them into a cancer-targeting tool after being removed from the culprit tumor. The TIL approach presents a robust response against advanced melanoma, the type that has shrugged off other approved therapies, providing a beacon of hope to those with limited treatment horizons.
Prof. Daniels, the lead investigator of the clinical trials that paved the way for this recent approval, highlighted in the trials the favorable outcomes of TIL therapy compared to existing frontline treatments for melanoma progression. This development is built on the last few years' decline in melanoma deaths, with a 5% annual decrease credited to advancements in treatment and sustained research efforts.
Melanoma figures denote it as the deadliest among skin cancers. Yet, it represents only nearly 1% of skin cancer cases in the U.S. With TIL's addition, UC San Diego Health solidifies its reputation as a heavyweight in revolutionary cancer therapies, baring its teeth against cancers that have metastasized and offering a pioneering health system dedicated to cancer immunotherapy, as expressed by Ayad Hamdan, MD, of Moores Cancer Center. The T-cells are augmented and returned to the patient's body to enhance their cancer-fighting prowess.
Diane Simeone, MD, director of Moores Cancer Center, takes pride in their ability to churn out leading-edge treatments like TIL therapy, a testament to the distinction of being an NCI-designated Comprehensive Cancer Center. Simeone attributes this success to the incredible team that crafts and executes clinical trials, ensuring new treatments make it from lab to patient bedside.
With this recent development, UC San Diego Health continues to broaden its array of innovative cancer treatments. Offering CAR T-cell therapy for certain blood cancers, they merge commitment and futuristic strategy in the battle against advanced cancers. This dedication to trailblazing treatment aligns with the persistent quest to serve patients with advanced cancers, a cohort often sidelined by traditional treatment modalities. As recognized in the latest U.S. News & World Report rankings, their cancer services are in the nation's top echelons, rooted in extensive research and personalized care.
